Oncology PracticeGenomic differences seen in mRCC during first- and second-line therapyFebruary 28, 2017Genitourinary CancerRenal Cell CarcinomaImmuno-oncology
Oncology PracticeActive surveillance an option for patients with mRCCFebruary 28, 2017Genitourinary Cancer
Oncology PracticeSingle BEP adjuvant chemotherapy cycle ‘sufficient’ in testicular cancerFebruary 23, 2017Genitourinary Cancer
Oncology PracticeChemoradiation standard of care in muscle-invasive bladder cancerFebruary 23, 2017Genitourinary Cancer
Oncology PracticeNew significantly mutated genes detected in prostate cancerFebruary 23, 2017Genitourinary Cancer
Oncology PracticeNo AR in CTCs linked with better survival in advanced prostate cancerFebruary 17, 2017Genitourinary Cancer
Oncology PracticeSurvival gains with pembrolizumab in urothelial cancerFebruary 17, 2017Genitourinary Cancer
Oncology PracticeRNA-based biopsy test bests NCCN risk stratification for PC prognosisFebruary 17, 2017Genitourinary Cancer
Oncology PracticeClinical benefit persists for some with mRCC after stopping immune checkpoint blockadeFebruary 15, 2017Genitourinary CancerRenal Cell Carcinoma
Oncology PracticeAntibiotic use may hamper checkpoint inhibitors for mRCCFebruary 14, 2017Genitourinary Cancer
Oncology PracticeCirculating tumor DNA could guide therapy for advanced prostate cancerFebruary 14, 2017Genitourinary Cancer
Oncology PracticeStaying the course after first progression yields better mRCC survivalFebruary 10, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeGU Cancers Symposium to feature latest on immune checkpoint inhibitors, circulating tumor cellsFebruary 7, 2017Genitourinary Cancer
Oncology PracticeFDA approves nivolumab for advanced urothelial carcinomaFebruary 2, 2017Genitourinary Cancer
